Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
June 16, 2020
Assignee:
TECHNISCHE UNIVERSITÄT GRAZ
Inventors:
Christiane Luley, Thornthan Sawangwan, Bernd Nidetzky, Mario Müller
Abstract: Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
June 16, 2020
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Brett E. Crawford, Jillian R. Brown, Charles A. Glass
Abstract: The disclosure discloses a preparation method of outer core octasaccharide of Helicobacter pylori lipopolysaccharide, and belongs to the field of carbohydrate chemistry. The structure of the outer core octasaccharide of Helicobacter pylori is (?-D-Glc-(1-3)-?-D-Glc-(1-4)-?-D-Gal-(1-7)-D-?-D-Hep[?-D-Glc-(1-6)-?-D-Glc-(1-6)-?-D-Glc-(1-2)-D-?-D-Hep]-Linker. The structure consists of three monosaccharides: glucose, galactose and heptose. It contains five ?-glycosidic bonds of glucose, one ?-glycosidic bond of galactose and two ?-glycosidic bonds of heptose. The disclosure prepares the octasaccharide by the synergistic action of remote neighboring group participation effect, solvent effect, temperature effect, additives and leaving groups. The reducing end of the octasaccharide may also be linked with a linker for future attachment to the protein to form a glycoconjugate for immunological studies.
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
June 2, 2020
Assignee:
Jiangnan University
Inventors:
Jian Yin, Jing Hu, Peter Seeberger, Xiaopeng Zou
Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
May 12, 2020
Assignee:
National Research Council of Canada
Inventors:
Dennis M. Whitfield, G. Dennis Sprott, Lakshmi Krishnan
Abstract: The invention relates to a composition comprising one or more antimicrobial glycolipids and one or more formulation stabilizers. The invention also relates to methods of preparing the compositions and their application in water containing food, beverage, cosmetic, home care and medical products.
Abstract: Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
May 5, 2020
Assignee:
Henry Ford Health System
Inventors:
Jae Ho Kim, Stephen L. Brown, Andrew Kolozsvary
Abstract: Compositions are disclosed herein comprising at least one dextran ether compound that comprises uncharged, anionic, and/or cationic organic groups. The degree of substitution of one or more dextran ether compounds is about 0.0025 to about 3.0. Dextran from which the disclosed ether compounds can be derived can have a weight-average molecular weight of about 50-200 million Daltons and/or a z-average radius of gyration of about 200-280 nm. Also disclosed are methods of producing dextran ether compounds, as well as methods of using these ether compounds in various applications.
Abstract: A process and equipment assembly for reacting a substituent precursor with a cyclodextrin starting material to provide a raw product comprising a cyclodextrin derivative and 1% or less of an initial amount of the substituent precursor is provided. The process of the present invention provides cyclodextrin derivatives in substantially shorter time and with fewer side products than previous processes that utilize substantially the same starting materials.
Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
Type:
Grant
Filed:
December 17, 2014
Date of Patent:
April 14, 2020
Inventors:
Dania Birte Reiche, Silke Haag-Diergarten, Leah Jeanette Hennings, Saskia Kley, Anne M. Traas
Abstract: The subject-matter of the present invention is an anhydrous cosmetic composition comprising, in a physiologically acceptable medium: at least one nonionic surfactant, at least one anionic surfactant, at least 25% of at least one filler. The article is partially or completely soluble in water and it constitutes a foaming product used for cleansing the skin and hair and/or removing makeup from the skin and/or as scrubbing product.
Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
Abstract: The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight.
Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.
Type:
Grant
Filed:
January 26, 2016
Date of Patent:
March 24, 2020
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Chakkumkal Anish, Marilda Lisboa, Christopher Martin, Claney Lebev Pereira, Peter H. Seeberger, Naeem Khan
Abstract: A method of deprotecting a solid support bound polynucleotide comprising at least one 2?-protected ribonucleotide in which a step of contacting the polynucleotide with a composition comprising a diamine is performed under conditions sufficient to deprotect and cleave the polynucleotide which remains retained on the solid support.
Type:
Grant
Filed:
December 12, 2017
Date of Patent:
March 24, 2020
Assignee:
Agilent Technologies, Inc.
Inventors:
Douglas J. Dellinger, Joel Myerson, Agnieszka Sierzchala, Geraldine F. Dellinger, Zoltan Timar
Abstract: The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).
Abstract: A mixture of human milk oligosaccharides that consists essentially of 3?-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-O-fucosyl-3?-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3?-O-sialyllactose and component A with an ?2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
March 17, 2020
Assignee:
GLYCOM A/S
Inventors:
Elise Champion, Bruce McConnell, Gyula Dekany
Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
March 17, 2020
Assignee:
N.V. Nutricia
Inventors:
Bernd Stahl, Alma Jildou Nauta, Johan Garssen, Eric Samain, Sophie Drouillard
Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
Type:
Grant
Filed:
August 3, 2016
Date of Patent:
February 25, 2020
Assignee:
Tolero Pharmaceuticals, Inc.
Inventors:
David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
Abstract: The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.
Abstract: Topical composition for the treatment of mucosal lesions It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
February 18, 2020
Assignees:
FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
Inventors:
Vicente María Lorenzo-Zúñiga García, Ramon Bartolí Solé, Jaume Boix Valverde